跳转至内容
Merck

PZ0012

Sigma-Aldrich

Sunitinib malate

≥98% (HPLC), powder, receptor tyrosine kinase inhibitor

别名:

N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt, SU 011248, SU 11248, SU112248

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H27FN4O2 · C4H6O5
分子量:
532.56
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

product name

Sunitinib malate, ≥98% (HPLC)

化驗

≥98% (HPLC)

形狀

powder

溶解度

DMSO: >10 mg/mL

儲存溫度

room temp

SMILES 字串

O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C

InChI

1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1

InChI 密鑰

LBWFXVZLPYTWQI-IPOVEDGCSA-N

正在寻找类似产品? 访问 产品对比指南

應用

Sunitinib malate has been used:
  • to study its mechanism in the inhibition of MCF-7 cell migration and angiogenesis
  • as a reference molecule to compare its docking energies with other ligands/vascular endothelial growth factor receptor (VEGF) receptor blocker
  • used in proliferation assay

生化/生理作用

Sunitinib has greater bioavailability and potency compared to other inhibitors. It prevents angiogenesis.
Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug.

特點和優勢

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Repr. 1B - STOT RE 1 Oral

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sunitinib: from rational design to clinical efficacy
Chow LQM and Eckhardt SG
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(7), 884-896 (2007)
Sunitinib treatment inhibited human breast cancer cell migration through regulation furin interaction with substrates
Jin SJ, et al.
International Journal of Clinical and Experimental Medicine, 9(2), 2535-2541 (2016)
Iris Uribesalgo et al.
EMBO molecular medicine, 11(8), e9266-e9266 (2019-07-04)
Angiogenesis is a hallmark of cancer, promoting growth and metastasis. Anti-angiogenic treatment has limited efficacy due to therapy-induced blood vessel alterations, often followed by local hypoxia, tumor adaptation, progression, and metastasis. It is therefore paramount to overcome therapy-induced resistance. We
Michael P Stany et al.
PloS one, 6(7), e21121-e21121 (2011-07-15)
Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer prognosis than serous and endometrioid histotypes. Despite this, patients with these tumors are treated in a similar fashion as all other
Suma Choorapoikayil et al.
Disease models & mechanisms, 6(5), 1159-1166 (2013-05-31)
Angiogenesis, the emergence of vessels from an existing vascular network, is pathologically associated with tumor progression and is of great interest for therapeutic intervention. PTEN is a frequently mutated tumor suppressor and has been linked to the progression of many

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门